ArticleThoracic cancer2021

Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells.

Mi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.